5 September 2017 - - The allergy diagnostics market is expected to reach USD 5.74bn by 2022 from USD 3.49bn in 2017, at a CAGR of 10.5% from 2017 to 2022, according to a report from Indian research firm MarketsandMarkets.

A high incidence of allergic diseases is one of the major factors driving the growth of this market.

The rising environmental pollution levels and the growing need for relatively faster, accurate, and high-throughput technologies for allergy diagnostics are the major factors supporting the growth of this market.

On the basis of product and service, the allergy diagnostic market is segmented into assay kits, instruments, and services. The instruments segment is further sub segmented into immunoassay analyzers, luminometers, ELISA analyzers, and other instruments.

The assay kits segment is expected to dominate the global Allergy Diagnostics Market in 2017.

Efficient performance, reliability, and great level of precision are key drivers increasing the demand for assay kits.

On the basis of allergens, the Allergy Diagnostics Market is segmented into inhaled allergens, food allergens, drug allergens, and other allergens. In 2017, the inhaled allergens segment is expected to account for the largest share of the Allergy Diagnostics Market.

Increasing environmental pollution is one of the major factors driving the growth of this segment.

Based on region, the Allergy Diagnostics Market is segmented into North America, Europe, Asia, and the Rest of the World. In 2017, North America is expected to command the largest share of the Allergy Diagnostics Market.

The large share of this segment can primarily be attributed to the increasing healthcare expenditure, coverage of allergy diagnostics tests in medical insurance, and the strong presence of players in this region.

Key players in the Allergy Diagnostics Market include Thermo Fisher Scientific Inc., Siemens AG (Germany), Danaher Corp., Omega Diagnostics Group PLC, Hitachi Chemical Co., Ltd. (Japan), bioMérieux SA (France), Stallergenes Greer, HOB Biotech Group Suzhou Co., Ltd. (China), HYCOR Biomedical, Lincoln Diagnostics, Inc., EUROIMMUN AG (Germany), INDOOR Biotechnologies, Inc., DR. FOOKE - Achterrath Laboratorien GmbH (Germany), R-Biopharm AG (Germany), GA Generic Assays GmbH (Germany), Tecan Trading AG (Switzerland), DST Diagnostische Systeme and Technologien GmbH (Germany), ROXALL Medical GmbH (Germany), ALK-Abelló A/S (Denmark), Astra Biotech GmbH (Germany), HAL Allergy Group (Netherlands), Theradiag (France), and Demeditec Diagnostics GmbH (Germany).